EICHORPublic-registry site landscape for NCT07675811, “A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy”, a Allergic Conjunctivitis study sponsored by Regeneron Pharmaceuticals. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07675811 (registry record) |
| Study title | A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy |
| Official title | A Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Participants With Allergic Conjunctivitis Due to Cat Allergy |
| Sponsor | Regeneron Pharmaceuticals |
| Condition(s) | Allergic Conjunctivitis |
| Phase | PHASE3 |
| Listed sites | 0 |
| Intervention(s) | REGN-2Cat, Freneslerbart, Mevonlerbart, Placebo |
Patient-friendly overview of this study: eichor.com/study/NCT07675811.
Eichor generates a preliminary site-risk snapshot for NCT07675811 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Allergic Conjunctivitis trials
More from Regeneron Pharmaceuticals
← Eichor home · All tracked trials · Allergic Conjunctivitis studies · Weekly briefs
